A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

NCT05813795 on ClinicalTrials.gov · last registry update 2025-04-30

Finished 20 June 2024, after enrolling 664 people. Primary outcome, as filed: Percent change in body weight from baseline. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.

Status: COMPLETED
Phase: P3
Drug: ecnoglutide
Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Sponsor type: Industry
Enrollment: 664
Started: 2023-04-05
Primary completion: 2024-06-20 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent change in body weight from baseline

Conditions studied

Weight Management

Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.